Comparison of In Vitro and Vivo Efficacy of Caspofungin Against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans

Efficacy of a Single 6 mg/kg versus Two 3 mg/Kg Caspofungin Doses for Treatment of Disseminated Candidiasis Caused byCandida albicansin a Neutropenic Mouse Model

(2014) S. Bayegan et al.   JOURNAL OF CHEMOTHERAPY

Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin againstCandida speciesusing time-kill methodology

(2012) Judit Szilágyi et al.   JOURNAL OF CHEMOTHERAPY

Efficacy of Caspofungin in a Juvenile Mouse Model of Central Nervous System Candidiasis

(2011) Amy M. Flattery et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Improved Detection of Candida sp.fksHot Spot Mutants by Using the Method of the CLSI M27-A3 Document with the Addition of Bovine Serum Albumin

(2011) Guillermo Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

In Vitro Fungicidal Activities of Echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis Evaluated by Time-Kill Studies

(2010) E. Canton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

(2010) Elizabeth M. Migoya et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Antifungal Activity of Micafungin in Serum

(2009) J. Ishikawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

(2009) Robert F. Betts et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time–kill methodology

(2009) Zsuzsa Szabó et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis: Results from Population-Based Surveillance of Candidemia in Spain

(2008) A. Gomez-Lopez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Significant differences in drug susceptibility among species in the Candida parapsilosis group

(2008) Eveline van Asbeck et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy

(2008) N. Kabbara et al.   HAEMATOLOGICA

Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis

(2008) I. Varga et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis

(2008) S. R. Lockhart et al.   JOURNAL OF CLINICAL MICROBIOLOGY